BioSpace News Archive

Greenhouse gas emissions intensity lowered by 16% and plastic footprint down 9.6% vs. 2020 Commitment to ambitious climate goals: Net-zero by 2050, Scope 1 and 2 emissions down 42% by 2030 Widening access to healthcare in high-burden, low-resource countries.

Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, announced the grant of inducement equity awards to the company’s newly appointed chief financial officer, Geoffrey Porges, MBBS.

DotLab, a medical diagnostics company, announced that the United States Patent and Trademark Office has granted three key patents for its technology focused on the diagnosis, assessment, and characterization of endometriosis.

Vifor Fresenius Medical Care Renal Pharma is pleased to announce that England’s National Institute for Health and Care Excellence has recommended Tavneos® in combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, active granulomatosis polyangiitis or microscopic polyangiitis, two main forms of AAV.

Valneva SE a specialty vaccine company, announced that the U.S. Department of Defense has decided not to exercise the second option year of the contract1 to supply Valneva’s Japanese encephalitis vaccine IXIARO®.

On May 19th, the European Medicines Agency announced that it had adopted a positive opinion regarding the application for conditional approval of Kinpeygo® for the treatment of IgA nephropathy, and on July 15th the European Commission issued the market authorization for Kinpeygo in the European Economic Area.

iZafe Group AB has signed a Letter of Intent with Pilloxa AB regarding the acquisition of 100 percent of the shares in Pilloxa.

GenScript USA Inc., a subsidiary of GenScript Biotech Corporation, a world-leading biotechnology company, announced the immediate availability of a monkeypox virus PCR test kit.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Saudi Food and Drug Authority (SFDA) has approved oral, once-daily ORLADEYO ® (berotralstat) to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older in Saudi Arabia.

Trial Library, Inc., an oncology clinical trials company, announced it has come out of stealth mode and received its first funding to address the need for equity in patient recruitment to oncology clinical trials.